Stock AnalizNovoCure Ltd NVCR
Medical/Dental Instruments · IPO 2015 · data as of November 13, 2026
NovoCure Ltd (NVCR) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $725M and net income of -$122M, a net margin of -16.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $725M | $655M | $605M | $509M | $538M | $535M | $494M | $351M | $248M | $177M | $83M |
| Net income | -$122M | -$136M | -$169M | -$207M | -$93M | -$58M | $20M | -$7M | -$64M | -$62M | -$132M |
| Free cash flow | -$25M | -$76M | -$69M | -$100M | $9M | $59M | $84M | $16M | -$9M | -$40M | -$113M |
| EPS (diluted) | $-1.06 | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.18 | $-0.07 | $-0.69 | $-0.70 | $-1.54 |
| Net margin | -16.8% | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% | -2.1% | -25.6% | -34.8% | -159.1% |
| ROIC | — | -26.1% | -12.9% | -19.0% | -6.9% | -3.5% | 2.6% | -0.2% | -10.2% | -14.7% | -38.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $26.14, 121% above the current price; targets range from $15.00 to $52.00; the consensus rating is “Buy”; expected EPS is $-1.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is NovoCure stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does NovoCure pay a dividend?
Not currently.
Is NovoCure a good stock to buy?
We do not give buy or sell advice. NovoCure scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.